## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

serdexmethylphenidate and dexmethylphendiate (Azstarys)

## Notes:

- Quantity Limits: Yes
- ^ Adequate trial of a long acting agent is further defined as wearing off that is not resolved by
  increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR
  clinically significant side effects related to the dosage form that cannot be resolved by adjusting the
  dose or timing.
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<u>Initiation (new start) criteria</u>: Non-formulary **serdexmethylphenidate and dexmethylphendiate (Azstarys)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial<sup>^</sup> of a methylphenidate or dexmethylphenidate product or patient has intolerance<sup>\*</sup> to methylphenidate
- Patient has failed an adequate trial<sup>^</sup> of an amphetamine or dextroamphetamine product or patient has intolerance\* to amphetamine and dextroamphetamine
- Patient has failed an adequate trial<sup>^</sup> of lisdexamfetamine or patient has intolerance<sup>\*</sup> to lisdexamfetamine

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary serdexmethylphenidate and dexmethylphendiate (Azstarys) will be covered on the prescription drug benefit for \*\*\* months when the following criteria are met:

- Patient has a diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient is already stable on serdexmethylphenidate and dexmethylphenidate (Azstarys)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary
<u>serdexmethylphenidate and dexmethylphendiate (Azstarys)</u> will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient is age 6 to 20 years old OR
- Patient has failed an adequate trial<sup>^</sup> of a methylphenidate or dexmethylphenidate product or patient has intolerance\* to methylphenidate
- Patient has failed an adequate trial<sup>^</sup> of an amphetamine or dextroamphetamine product or patient has intolerance<sup>\*</sup> to amphetamine and dextroamhpetamine

kp.org

Effective: 2/15/23

All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

serdexmethylphenidate and dexmethylphendiate (Azstarys)

 Patient has failed an adequate trial<sup>^</sup> of lisdexamfetamine or patient has intolerance<sup>\*</sup> to lisdexamfetamine

NOTE: If information is not available in Care Everywhere and patient is unable to verify in an interview, the patient or new provider will need to request outside records from previous provider(s).

. . .

kp.org

Effective: 2/15/23 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

